Zangerle John Adam sold $297K of STE

Zangerle John Adam (Sr. VP, Gen Counsel, and Sec.) sold 1,419 shares of STERIS plc (STE) at $209.28 ($0.30M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zangerle John Adam
Published Jun 16, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
high confidence
Mentioned
$STE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; no other company-specific developments are provided.

02

Market read

This provides incremental transparency on insider activity but lacks fundamental catalysts, so trading impact is likely limited.

03

What to watch

Traders may overreact to insider sales; without changes in guidance, contracts, or litigation, the incremental information is mostly sentiment-level.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-15.

Background

The article is a SEC Form 4 insider transaction disclosure for STERIS plc.

Company-level read

Ticker impact

$STENeutralHigh confidence
Context

STERIS disclosed an officer’s open-market sale of 1,419 shares at $209.28 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying fundamental or regulatory catalyst.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because it’s a pre-arranged 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • STERIS plc

    Subject of the Form 4 insider transaction disclosure.

  • Zangerle John Adam

    Sr. VP, General Counsel, and Secretary; reported an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STEMedAI 8/10

STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland and a wholly-owned subsidiary of STERIS plc, a public…

STERIS plc (STE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 9, 2026, STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland (the “Issuer”) and a wholly-owned subsidiary of STERIS plc, a public limited company incorporated under the laws of Ireland (the “C

$STEMed

What STERIS (STE) Said on Its Q2 Earnings Call

STERIS (STE) reported Q2 adjusted EBIT margin up 150 bps to 24.6%, with EPS growth of 13% excluding refunds. Life Sciences revenue rose 18%, leading to an increased full-year growth forecast of 9-10%. AST segment revenue grew 5%, but its forecast was lowered to 6-7%. The company announced a $45M restructuring plan and expects its Xodus Medical acquisition to boost revenue and margins.

$STEMed

Steris PLC (STE) (Q2 2027) Earnings Call Highlights: Revenue Climbs 9%

STERIS PLC reported Q2 2027 revenue up 9%, but EBIT margins declined in both Healthcare and AST segments due to inflation and other factors. AST revenue growth guidance was lowered. Free cash flow decreased. A $45M restructuring plan was announced. CEO Dan Carestio discussed growth opportunities, including the Xodus Medical acquisition, and addressed margin pressures and market dynamics.

$STEHighAI 8/10

STERIS (STE) Q2 2027 Earnings Call Transcript

STERIS (STE) reported Q2 2027 earnings with adjusted EBIT margin at 24.6%, up 150 bps YoY. Adjusted EPS grew 19% to $2.94. Revenue grew 7-8%, with Healthcare up 7%, AST up 5%, and Life Sciences up 18%. The company announced plans to acquire Xodus Medical. Full-year EPS outlook raised to $11.35-$11.55. Free cash flow was $492.5M for H1 2027.

$CATMedAI 8/10

Caterpillar's $1B Sanford Plant Fuels Raleigh-Durham Growth

Caterpillar plans to invest $1B in a North Carolina plant, expanding manufacturing capacity. The project is part of a broader industrial surge in Raleigh-Durham, with increased leasing activity and construction. Other companies, including AbbVie, Siemens, and Forge Nano, are also investing in the region. Research Triangle Park is diversifying with mixed-use and residential developments.